Rewalk Robotics (NASDAQ:RWLK) has been given a $3.00 target price by research analysts at Oppenheimer in a report issued on Monday. The brokerage presently has a “buy” rating on the medical device company’s stock. Oppenheimer’s price objective would suggest a potential upside of 165.49% from the stock’s current price.

Several other research analysts have also commented on RWLK. Jefferies Group reduced their price target on Rewalk Robotics from $8.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, November 3rd. Canaccord Genuity reiterated a “buy” rating and set a $3.00 price target on shares of Rewalk Robotics in a report on Monday, November 6th. Finally, Zacks Investment Research upgraded Rewalk Robotics from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a report on Thursday, November 9th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Rewalk Robotics has a consensus rating of “Buy” and an average target price of $2.80.

Rewalk Robotics (NASDAQ:RWLK) opened at $1.13 on Monday. Rewalk Robotics has a fifty-two week low of $1.05 and a fifty-two week high of $3.60. The company has a current ratio of 2.02, a quick ratio of 1.65 and a debt-to-equity ratio of 7.46. The company has a market capitalization of $31.82, a price-to-earnings ratio of -0.71 and a beta of 0.79.

Rewalk Robotics (NASDAQ:RWLK) last posted its quarterly earnings results on Thursday, November 2nd. The medical device company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.10. Rewalk Robotics had a negative return on equity of 568.25% and a negative net margin of 346.14%. The business had revenue of $1.70 million for the quarter, compared to analyst estimates of $1.63 million. During the same quarter in the previous year, the firm earned ($0.62) EPS. The company’s quarterly revenue was up 21.4% compared to the same quarter last year. research analysts expect that Rewalk Robotics will post -1.14 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of RWLK. Renaissance Technologies LLC raised its holdings in Rewalk Robotics by 61.7% in the 1st quarter. Renaissance Technologies LLC now owns 78,600 shares of the medical device company’s stock valued at $165,000 after buying an additional 30,000 shares during the period. Essex Investment Management Co. LLC raised its holdings in Rewalk Robotics by 328.7% in the 3rd quarter. Essex Investment Management Co. LLC now owns 156,981 shares of the medical device company’s stock valued at $228,000 after buying an additional 120,362 shares during the period. Finally, Advisor Group Inc. raised its holdings in Rewalk Robotics by 1,495.6% in the 3rd quarter. Advisor Group Inc. now owns 181,900 shares of the medical device company’s stock valued at $264,000 after buying an additional 170,500 shares during the period. Hedge funds and other institutional investors own 3.23% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at

About Rewalk Robotics

ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.

Receive News & Ratings for Rewalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rewalk Robotics and related companies with's FREE daily email newsletter.